← Back to Search

Other

FN-1501 for Acute Myelogenous Leukemia

Phase 1
Waitlist Available
Research Sponsored by Shanghai Fosun Pharmaceutical Development Co, Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during the first year.
Awards & highlights

Study Summary

A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

Eligible Conditions
  • Cancer
  • Solid Tumors
  • Acute Myelogenous Leukemia
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during the first year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and during the first year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.03
To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)
Secondary outcome measures
Apparent volume of distribution (Vd)
Area under concentration-time curve from 0 to 24 hours (AUC(0-24))
Area under the plasma concentration time curve from zero to infinity (AUC0-∞)
+7 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: FN-1501Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Shanghai Fosun Pharmaceutical Development Co, Ltd.Lead Sponsor
4 Previous Clinical Trials
816 Total Patients Enrolled
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Lead Sponsor
14 Previous Clinical Trials
5,018 Total Patients Enrolled
Ai-Min Hui, MD, PhDStudy DirectorShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
2018. "A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03690154.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top